Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y4AU
|
||||
| Former ID |
DNC013616
|
||||
| Drug Name |
CCNCSAKWCRDHSRCC
|
||||
| Indication | Discovery agent | Investigative | [529000] | ||
| Formula |
C70H106N28O21S6
|
||||
| Canonical SMILES |
CC1C(=O)NC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC3CSSCC(C(=O)NC(<br />CSSCC(C(=O)NC(C(=O)N1)CO)NC(=O)C(NC3=O)CC(=O)N)C(=O)N)N<br />C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCNC(=N)N<br />)CC(=O)O)CC4=CN=CN4)CO)CCCNC(=N)N)N)CC5=CNC6=CC=CC=C65)<br />CCCCN
|
||||
| InChI |
1S/C70H106N28O21S6/c1-31-54(105)85-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)59(110)97-48-27-122-120-24-35(72)55(106)95-47-26-124-125-29-50(68(119)94-46(53(74)104)25-121-123-28-49(67(118)93-44(22-99)63(114)84-31)98-61(112)42(18-51(73)101)90-66(47)117)96-58(109)39(12-7-15-81-70(77)78)86-64(115)45(23-100)92-60(111)41(17-33-21-79-30-83-33)89-62(113)43(19-52(102)103)91-57(108)38(87-65(48)116)11-6-14-80-69(75)76/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,114)(H,85,105)(H,86,115)(H,87,116)(H,88,107)(H,89,113)(H,90,117)(H,91,108)(H,92,111)(H,93,118)(H,94,119)(H,95,106)(H,96,109)(H,97,110)(H,98,112)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
|
||||
| InChIKey |
AOAFXQNJFCOYGE-CPQFHPGLSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium channel protein type 4 subunit alpha | Target Info | Inhibitor | [529000] | |
| Reactome | Interaction between L1 and Ankyrins | ||||
| References | |||||